The original version of this article failed to report that Stratagene posted a decline in fourth-quarter 2006 revenue because of one-time settlement income received from Cambridge Antibody Technology during the fourth quarter of 2005.
 
NEW YORK (GenomeWeb News) — Stratagene yesterday said fourth-quarter revenues fell 57 percent as R&D spending dipped 18 percent and profit increased 350 percent as the company settled an expensive patent-litigation suit with Third Wave Technologies.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.